文献速递皮肤肿瘤

薄层黑色素瘤管理中核分裂率是否仍有用?

Is mitotic rate still useful in the management of patients with thin melanoma?
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-08-22

该多中心回顾性研究分析203例≤1mm黑色素瘤患者,用CART算法寻找前哨淋巴结(SLN)阳性预测因素。T1a患者SLN阳性可能性7.5%;T1b中核分裂率>1个/mm²者14.3%,≤1个/mm²者3.2%。T1b中核分裂率≤1个/mm²且伴回归者无SLN阳性。

要点

  • T1a黑色素瘤SLN阳性可能性为7.5%。
  • T1b且核分裂率≤1个/mm²者SLN阳性仅3.2%。
  • T1b且核分裂率≤1个/mm²并伴回归者无SLN阳性。

核心结论

  • T1b黑色素瘤中核分裂率≤1个/mm²者SLN转移较少,该亚组应谨慎考虑SLN活检。

研究设计与样本

  • 回顾性多中心观察性研究,分析203例厚度≤1mm的黑色素瘤患者。
  • 采用分类与回归树(CART)方法识别预测因素,用Kaplan-Meier曲线估计黑色素瘤特异性生存。

主要发现

  • 按新AJCC分期标准,CART算法识别T1a患者SLN阳性可能性为7.5%。
  • T1b黑色素瘤中,核分裂率>1个/mm²者SLN阳性可能性为14.3%,≤1个/mm²者为3.2%。
  • T1b疾病中核分裂率≤1个/mm²且伴回归的患者无SLN阳性。
  • T1b患者中,SLN阴性组5年黑色素瘤特异性生存率为98.7%,SLN阳性组为75%(P=0.05)。
  • 按核分裂率分层,≤1个/mm²者生存率100%,>1个/mm²者91.4%(P=0.022);T1a亚组无死亡。

临床怎么用

  • 对T1b黑色素瘤且核分裂率≤1个/mm²者,尤其伴回归时,应仔细权衡SLN活检的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: T1 melanoma substaging was recently modified by the American Joint Committee on Cancer (AJCC). Although sentinel lymph node (SLN) positivity is the most important prognostic factor in melanoma, there is a lack of consensus on whether SLN biopsy should be performed in patients with thin melanoma (≤1 mm). OBJECTIVE: The main aim of this study was to investigate predictors of SLN positivity in patients with thin melanoma, with a special emphasis on mitotic rate. A secondary aim was to evaluate survival in this group of patients. MATERIALS AND METHODS: Retrospective multicenter observational study with analysis of age, sex, tumour location, thickness, mitotic rate, regression and microscopic satellites. Predictive factors were identified using a classification and regression tree (CART) approach. Melanoma-specific survival according to SLN status was estimated using Kaplan-Meier curves. RESULTS: We analysed 203 patients with a melanoma ≤1 mm. Using the new AJCC staging criteria, the CART algorithm identified a 7.5% likelihood of SLN positivity in T1a patients. In the case of T1b melanoma, there was a 14.3% likelihood of SLN positivity in patients with a mitotic rate >1 mitosis/mm2 and a 3.2% likelihood in those with ≤1 mitoses/mm2 . None of the patients with T1b disease who had ≤1 mitoses/mm2 and regression had SLN positivity. In T1b patients, 5-year melanoma-specific survival was 98.7% in the SLN-negative group and 75% in the SLN-positive group (P = 0.05). When stratified by mitotic rate, survival was 100% for patients with a mitotic rate of ≤1 mitoses/mm2 and 91.4% for those with >1 mitosis/mm2 (P = 0.022). There were no deaths in the T1a subgroup. CONCLUSIONS: Sentinel lymph node metastasis was less common in patients with T1b melanoma who had a mitotic rate of ≤1 mitoses/mm2 . Performance of SLN biopsy should be carefully considered in this subgroup of patients, particularly considering the good prognosis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Tejera-Vaquerizo A, Pérez-Cabello G, Marínez-Leborans L, et al. Is mitotic rate still useful in the management of patients with thin melanoma? J Eur Acad Dermatol Venereol. 2017. PMID: 28750139. doi:10.1111/jdv.14485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。